The Massachusetts Biotechnology Council (MassBio) today released its State of Possible 2025 Report, a five-year strategic plan to define the future direction of the Massachusetts life sciences ecosystem and highlight the many systemic challenges that require attention for the cluster to stay ahead of the curve on scientific innovation. The report will also serve as a call to action to drive cross-industry collaboration in order to overcome shared challenges, capitalize on Massachusetts’ greatest assets, and develop strategic economic development.
Through interviews and consultations with government, academic, and industry leaders, this report, prepared by Deloitte, found that the Massachusetts life sciences community is expected to achieve balanced growth over the next five years. Some of the areas include expanding R&D beyond oncology and rare diseases as well as positioning the state as a center for medical technology.
The report also calls attention to some gaps for improvement needed for the industry to thrive and grow sustainably. Some of these gaps are the availability of funding and the lack of affordable space and an efficient transportation system.
For more information on the full report, click here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.